The Impact of the G6PD Gene Mutations in Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals: A Multicenter Observational Study
Genes · 2024
DOI: 10.3390/genes15091116 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Genes, 2024. Verfasst von Carlo Smirne und 7 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Unit, Maggiore della Carità Hospital, 28100 Novara, Italy. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis C, Chronic, Glucosephosphate Dehydrogenase, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Following the advent of direct-acting antivirals (DAAs), the treatment of hepatitis C virus (HCV) infection is now rarely challenging. However, data are still limited concerning DAA use in patients affected by glucose-6-phosphate dehydrogenase deficiency (G6PDd). Based on these considerations, the goal of this study was to evaluate the effectiveness and safety of DAAs in this subpopulation. A retrospective multicenter observational study (2015–2023) was conducted on all 2754 consecutive HCV-positive patients treated with first- and second-generation all-oral DAAs, and with a G6PDd diagnosis confirmed by quantitative testing (n = 38). At the treating clinician’s discretion, an enhanced clinical and laboratory follow-up was performed, generally on a monthly basis both during treatment and up to six months after the end of it. Concerning hematochemical parameters, no significant differences were found between any considered time point. In all cases, no treatment-related adverse events were reported, and virologic response rates were as expected without G6PDd. In conclusion, in a large experience which, to the best of our knowledge, is unprecedented in the literature, the treatment of HCV hepatitis with nearly all available DAAs in patients with G6PDd as a comorbidity—a common occurrence in countries such as Italy—proved to be highly effective and safe.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine Unit, Maggiore della Carità Hospital, 28100 Novara, Italy.
- Department of Translational Medicine, University of Piemonte Orientale, 28100 Novara, Italy.
- Laboratory of Molecular Virology, Maggiore della Carità Hospital, 28100 Novara, Italy.
- Clinical Biochemistry Laboratory, City of Health and Science University Hospital, 10126 Turin, Italy.
- Division of Endocrinology, Diabetes and Metabolism, City of Health and Science University Hospital, 10126 Turin, Italy.
- Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
ORCID-Profile: Carlo Smirne, Alessandro Maria Berton, Barbara Pasini, Mario Pirisi
Zitieren
APA
Smirne, C., Crobu, M. G., Gerevini, C., Berton, A. M., Rapetti, R., Pasini, B., Ravanini, P., & Pirisi, M. (2024). The Impact of the G6PD Gene Mutations in Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals: A Multicenter Observational Study. Genes. https://doi.org/10.3390/genes15091116
Vancouver
Smirne C, Crobu MG, Gerevini C, Berton AM, Rapetti R, Pasini B, et al. The Impact of the G6PD Gene Mutations in Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals: A Multicenter Observational Study. Genes. 2024. doi:10.3390/genes15091116
BibTeX
@article{Smirne2024,
author = {Smirne, Carlo and Crobu, Maria Grazia and Gerevini, Chiara and Berton, Alessandro Maria and Rapetti, Rachele and Pasini, Barbara and Ravanini, Paolo and Pirisi, Mario},
title = {The Impact of the G6PD Gene Mutations in Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals: A Multicenter Observational Study},
journal = {Genes},
year = {2024},
doi = {10.3390/genes15091116}
}
EUVIMED